(DCPH) – Hot FDA News
-
Deciphera Pharmaceuticals (DCPH) MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Met Primary Endpoint
-
Deciphera Pharmaceuticals (DCPH) INTRIGUE Phase 3 Clinical Study Did Not Meet the Primary Endpoint in GIST
-
-
-
-
-
Back to DCPH Stock Lookup